Feb 6 (Reuters) - Biogen forecast 2026 profit above Wall Street estimates on Friday, banking on demand for newer medicines ...

Biogen swung to a loss as results were hurt by a double-digit decline in revenue from its core multiple sclerosis treatments.

US biotech major Biogen (Nasdaq: BIIB) has elected Maria Freire as chair of the board of directors. She will take up the role ...

On February 11, 2026, Biogen announced that Caroline Dorsa, Chair of the company’s Board of Directors, will not stand for re-election at the 2026 Annual Meeting of Stockholders. The company stated ...

Biogen recorded declining sales for Spinraza in each of the four quarters of 2025, but the Massachusetts drugmaker sees ...

Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new ...

Biogen (NASDAQ:BIIB) executives said the company ended 2025 “slightly above the upper end” of its guidance, pointing to ...

A federal judge in Illinois allowed a class action against Biogen Inc. to advance over the drugmaker’s alleged collusion with pharmacy benefit managers to favor its multiple sclerosis drug Tecfidera ...

Biogen Inc. (NASDAQ:BIIB) on Friday reported better-than-expected fourth-quarter earnings, with adjusted EPS of $1.99, beating the consensus of $1.59. The Alzheimer's drug maker reported revenues of ...

Biogen (BIIB) stock gains as the company beats estimates for Q4 2025 despite projecting a revenue decline for 2026. Read more ...

Biogen's fourth quarter saw the company book total revenue of almost $2.28 billion, down 7% year over year. Net income not in accordance with generally accepted accounting principles (GAAP) fell more ...

The uptick in Leqembi (lecanemab) sales comes a few months after the FDA approved a once-weekly subcutaneous injection ...